On Feb. 18, 2026, investors weighed ImmunityBio’s EU bladder cancer win against its long slide since IPO and fresh legal scrutiny.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results